This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Oxford BioMedica plc
Drug Names(s): MVA-5T4; SAR109659
Description: TroVax is Oxford BioMedica’s novel cancer immunotherapy product. It is designed specifically to stimulate an anti-cancer immune response and has potential application in most solid tumour types. TroVax targets the tumour antigen 5T4, which is broadly distributed throughout a wide range of solid tumours. The presence of 5T4 is correlated with poor prognosis. The product consists of a Modified Vaccinia Ankara vector, which delivers the gene for 5T4 and stimulates a patient’s body to produce an anti-5T4 immune response. This immune response destroys tumour cells carrying the 5T4.
Deal Structure: In March 2007, Oxford BioMedica and sanofi-aventis entered into an exclusive global licensing agreement to develop and commercialise TroVax for the treatment and prevention of cancers. Under the terms of this agreement, sanofi-aventis will pay Oxford BioMedica up to 518 million if all development and registration targets are met for certain defined indications. Additional payments will be made if regulatory milestones are achieved in other cancer types. Oxford BioMedica, along with initial payments, is also entitled to escalating royalties on global sales of TroVax and to further undisclosed commercial milestones when net sales of TroVax reach certain levels.
TroVax may be developed by sanofi-aventis as a treatment for any cancer type. Oxford BioMedica has an option to develop TroVax for other cancer types in exchange for enhanced financial returns, and sanofi-aventis will keep all commercial rights. Oxford BioMedica will supply TroVax to sanofi-aventis on commercial terms....See full deal structure in Biomedtracker
Additional information available to subscribers only: